LMG
0.016
60%
OVT
0.001
-50%
PNT
0.007
40%
IBR
0.026
-42.2%
AUR
0.019
26.7%
CGR
0.045
-39.2%
SLB
0.32
25.5%
BRY
0.013
-31.6%
CVB
0.025
25%
RPM
0.012
-20%
SRJ
0.005
25%
A8G
0.165
-17.5%
CYB
0.051
21.4%
H3E
0.005
-16.7%
PL9
0.006
20%
MHC
0.021
-16%
PLC
0.007
16.7%
AVW
0.006
-14.3%
DM1
0.008
14.3%
AX8
0.006
-14.3%
EQR
0.44
14.3%
NS1
0.006
-14.3%
IVZ
0.072
14.3%
VRS
0.04
-13%
DEL
0.1
13.6%
IVG
0.035
-12.5%
OD6
0.125
13.6%
PCL
0.007
-12.5%
EMD
0.053
12.8%
PSL
0.035
-12.5%
OR3
0.08
12.7%
AAU
0.008
-11.1%
AR9
0.063
12.5%
RAD
0.008
-11.1%
GTE
0.009
12.5%
DUN
0.041
-10.9%
WCN
0.019
11.8%
T92
0.042
-10.6%
VKA
0.01
11.1%
IMC
0.046
-9.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Arovella Therapeutics (ASX:ALA): A novel cell therapy treatment for cancers and tumours

Ahead of appearing at the Spark+ Australian Equities Day in Singapore, Arovella’s (ASX:ALA) CEO & Managing Director Dr Michael Baker speaks with The Stock Network’s Lel Smits about:

🩸 The current lead product coming out of Arovella Therapeutics’ cell therapy platform – ALA-101 – iNKT cells create receptors that target antigens
🩸 How ALA-101 targets cancers and tumours
🩸 Timing of Phase 1 trials for ALA-101

Watch the full interview ⚡️ https://youtu.be/Hb_HZmKYCNA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697